Xenon Pharmaceuticals Inc (NASDAQ: XENE) is -15.28% lower on its value in year-to-date trading and has touched a low of $26.74 and a high of $46.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The XENE stock was last observed hovering at around $32.17 in the last trading session, with the day’s loss setting it -31.13%.
Currently trading at $1.04M, the stock is 1.71% and -3.86% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.44 million and changing 1442659% at the moment leaves the stock -15.53% off its SMA200. XENE registered -18.98% loss for a year compared to 6-month loss of -18.35%. The firm has a 50-day simple moving average (SMA 50) of $33.034 and a 200-day simple moving average (SMA200) of $37.599125.
The stock witnessed a 6.76% gain in the last 1 month and extending the period to 3 months gives it a -9.00%, and is 0.19% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.78% over the week and 1.90% over the month.
Xenon Pharmaceuticals Inc (XENE) has around 327 employees, a market worth around $2.44B and $7.50M in sales. Profit margin for the company is -3352.61%. Distance from 52-week low is 18.77% and -30.96% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.35%).
The EPS is expected to shrink by -33.46% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
285.0 institutions hold shares in Xenon Pharmaceuticals Inc (XENE), with institutional investors hold 103.86% of the company’s shares. The shares outstanding are 76.59M, and float is at 74.39M with Short Float at 4.53%. Institutions hold 103.59% of the Float.
The top institutional shareholder in the company is FMR LLC with over 6.77 million shares valued at $263.89 million. The investor’s holdings represent 8.7139 of the XENE Shares outstanding. As of 2024-06-30, the second largest holder is AVORO CAPITAL ADVISORS LLC with 5.67 million shares valued at $220.94 million to account for 7.2957 of the shares outstanding. The other top investors are DRIEHAUS CAPITAL MANAGEMENT LLC which holds 4.42 million shares representing 5.69 and valued at over $172.32 million, while WELLINGTON MANAGEMENT GROUP LLP holds 4.9288 of the shares totaling 3.83 million with a market value of $149.26 million.
Xenon Pharmaceuticals Inc (XENE) Insider Activity
The most recent transaction is an insider sale by GANNON STEVEN, the company’s Director. SEC filings show that GANNON STEVEN sold 3 shares of the company’s common stock on Jun 05 ’25 at a price of $30.48 per share for a total of $91.0. Following the sale, the insider now owns 7141.0 shares.
Xenon Pharmaceuticals Inc disclosed in a document filed with the SEC on Jan 24 ’25 that MORTIMER IAN (PRESIDENT & CEO) sold a total of 22,468 shares of the company’s common stock. The trade occurred on Jan 24 ’25 and was made at $40.20 per share for $0.9 million. Following the transaction, the insider now directly holds 31302.0 shares of the XENE stock.
Still, SEC filings show that on Jan 27 ’25, MORTIMER IAN (PRESIDENT & CEO) disposed off 16,315 shares at an average price of $40.50 for $0.66 million. The insider now directly holds 31,302 shares of Xenon Pharmaceuticals Inc (XENE).
